[go: up one dir, main page]

MX2016008023A - Composiciones y metodos para inhibir la inflamacion y las enfermedades utilizando un compuesto antimicrobiano con base en acido alginico. - Google Patents

Composiciones y metodos para inhibir la inflamacion y las enfermedades utilizando un compuesto antimicrobiano con base en acido alginico.

Info

Publication number
MX2016008023A
MX2016008023A MX2016008023A MX2016008023A MX2016008023A MX 2016008023 A MX2016008023 A MX 2016008023A MX 2016008023 A MX2016008023 A MX 2016008023A MX 2016008023 A MX2016008023 A MX 2016008023A MX 2016008023 A MX2016008023 A MX 2016008023A
Authority
MX
Mexico
Prior art keywords
compositions
methods
alginic acid
antimicrobial compound
diseases
Prior art date
Application number
MX2016008023A
Other languages
English (en)
Inventor
Guthrie Wendell
Hahn Gary
Original Assignee
Evofem Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53403777&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2016008023(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Evofem Inc filed Critical Evofem Inc
Publication of MX2016008023A publication Critical patent/MX2016008023A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F6/00—Contraceptive devices; Pessaries; Applicators therefor
    • A61F6/02—Contraceptive devices; Pessaries; Applicators therefor for use by males
    • A61F6/04—Condoms, sheaths or the like, e.g. combined with devices protecting against contagion
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F6/00—Contraceptive devices; Pessaries; Applicators therefor
    • A61F6/06—Contraceptive devices; Pessaries; Applicators therefor for use by females
    • A61F6/065—Condom-like devices worn by females
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/734—Alginic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M35/00—Devices for applying media, e.g. remedies, on the human body
    • A61M35/003—Portable hand-held applicators having means for dispensing or spreading integral media
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Molecular Biology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente divulgación se refiere a composiciones y métodos para inhibir la inflamación y reducir el riesgo de propagación de enfermedades de transmisión sexual mediante el uso un compuesto antimicrobiano con base en ácido algínico. Tales composiciones proporcionan protección dual mediante (1) el ataque y la inactivación de virus y otros microbios y (2) el bloqueo de la respuesta del huésped que los virus activan para invadir las células huésped. Tales composiciones también pueden ser parte de un anticonceptivo de amortiguamiento de ácido.
MX2016008023A 2013-12-19 2014-12-19 Composiciones y metodos para inhibir la inflamacion y las enfermedades utilizando un compuesto antimicrobiano con base en acido alginico. MX2016008023A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361918445P 2013-12-19 2013-12-19
PCT/US2014/071664 WO2015095793A1 (en) 2013-12-19 2014-12-19 Compositions and methods for inhibiting inflammation and diseases using an alginic acid-based antimicrobial compound

Publications (1)

Publication Number Publication Date
MX2016008023A true MX2016008023A (es) 2017-01-13

Family

ID=53403777

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016008023A MX2016008023A (es) 2013-12-19 2014-12-19 Composiciones y metodos para inhibir la inflamacion y las enfermedades utilizando un compuesto antimicrobiano con base en acido alginico.
MX2021001742A MX2021001742A (es) 2013-12-19 2016-06-17 Composiciones y metodos para inhibir la inflamacion y las enfermedades utilizando un compuesto antimicrobiano con base en acido alginico.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021001742A MX2021001742A (es) 2013-12-19 2016-06-17 Composiciones y metodos para inhibir la inflamacion y las enfermedades utilizando un compuesto antimicrobiano con base en acido alginico.

Country Status (15)

Country Link
US (3) US11337989B2 (es)
EP (2) EP3082826B1 (es)
JP (3) JP2017501227A (es)
KR (1) KR102407408B1 (es)
CN (2) CN114452298A (es)
AU (2) AU2014368971B2 (es)
BR (1) BR112016014506B1 (es)
DK (1) DK3082826T3 (es)
ES (1) ES2790703T3 (es)
IL (1) IL246146B2 (es)
MX (2) MX2016008023A (es)
NZ (1) NZ722215A (es)
RU (1) RU2691950C1 (es)
WO (1) WO2015095793A1 (es)
ZA (1) ZA201604862B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ703203A (en) 2012-06-13 2016-07-29 Evofem Inc Compositions and methods for enhancing the efficacy of contraceptive microbicides
CN114452298A (zh) 2013-12-19 2022-05-10 伊沃菲姆股份有限公司 使用基于藻酸的抗微生物化合物抑制炎症和疾病的组合物和方法
DE102017110168A1 (de) 2016-05-25 2017-11-30 Samsung Electronics Co., Ltd. Elektronische Vorrichtung mit NFC-Antenne
WO2018049326A1 (en) * 2016-09-12 2018-03-15 Evofem Biosciences, Inc. Combination gel for sexually transmitted infections
EP3522879A4 (en) * 2016-10-04 2020-06-03 Evofem, Inc. Method of treatment and prevention of bacterial vaginosis
EP4422640A4 (en) * 2021-10-28 2025-11-19 Evofem Inc FAST-DISSOLVING VAGINAL FILM WITH CONTRACEPTIVE ACTION AND PREVENTION OF SEXUALLY TRANSMITTED INFECTION

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1213323B (it) 1986-08-07 1989-12-20 Crinos Industria Farmaco Composizione per uso locale ad atti vita' spermicida virulicida ,disinfettante e/o battericida
US4999342A (en) 1988-08-16 1991-03-12 Ortho Pharmaceutical Corporation Long lasting contraceptive suppository composition and methods of use
JP3202365B2 (ja) * 1992-12-04 2001-08-27 株式会社紀文フードケミファ オリゴマンヌロン酸を重合度によって分離する方法
US5592949A (en) 1994-06-29 1997-01-14 Moench; Thomas R. Device for acidic buffering and method for inactivation of pathogens
US5667492A (en) 1994-10-07 1997-09-16 Columbia Laboratories, Inc. Use and composition of an anti-sexually transmitted diseases formulation
FR2728464B1 (fr) 1994-12-22 1997-04-30 Innothera Lab Sa Forme galenique unitaire, son procede d'obtention et ses utilisations
US6093394A (en) 1997-04-11 2000-07-25 Gynelogix, Inc. Vaginal lactobacillus medicant
WO2001038284A1 (en) 1999-11-24 2001-05-31 Cargill Dow Llc Improved lactic acid processing; methods; arrangements; and, products
AU2001243431B2 (en) * 2000-03-07 2006-05-25 Rush University Medical Center Compositions and methods for trapping and inactivating pathogenic microbes and spermatozoa
JP2009102407A (ja) * 2001-03-08 2009-05-14 Rohto Pharmaceut Co Ltd Ｇリッチなアルギン酸含有組成物
US20020177624A1 (en) 2001-03-16 2002-11-28 Calvin Hanna Acetate-lactate buffering vaginal gel and for method of making same and treating bacterial vaginosis
ITMI20010913A1 (it) 2001-05-04 2002-11-04 Univ Pavia Composizioni a rilascio controllato di acido lattico a livello vaginale
CA2449247A1 (en) * 2001-06-11 2002-12-19 Merck & Co., Inc. A method for treating inflammatory diseases by administering a ppar-delta agonist
US20130150810A1 (en) 2002-04-30 2013-06-13 The Population Council, Inc. Intravaginal ring for the delivery of unique combinations of antimicrobial compositions
JP4712380B2 (ja) 2002-07-26 2011-06-29 三笠製薬株式会社 外用剤
US7820145B2 (en) 2003-08-04 2010-10-26 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
DK1635847T3 (da) 2003-06-13 2019-10-28 Idh Holding Aps Behandling af symptomer forbundet med bakteriel vaginose
US20050272700A1 (en) 2004-05-10 2005-12-08 Servet Buyuktimkin Topical treatment and prevention of human papilloma virus (HPV) infection
RU2257197C1 (ru) * 2004-05-12 2005-07-27 Дулькис Мария Дмитриевна Вагинальные суппозитории, обладающие контрацептивным действием
UA93354C2 (ru) 2004-07-09 2011-02-10 Гилиад Сайенсиз, Инк. Местный противовирусный препарат
US20100069323A1 (en) * 2006-11-10 2010-03-18 Rohto Pharmaceutical Co., Ltd. Composition for application to skin or mucosa
US7659259B2 (en) * 2006-12-21 2010-02-09 Bausch & Lomb Incorporated Method of treating inflammation of the eye
RU2459620C2 (ru) 2007-03-30 2012-08-27 Лаккуре Аб Применение олигомеров молочной кислоты в лечении гинекологических расстройств
AU2008256689A1 (en) 2007-05-24 2008-12-04 New York Blood Center Inc. Rapidly dispersible vaginal tablet that provides a bioadhesive gel
TW200927141A (en) 2007-11-22 2009-07-01 Bayer Schering Pharma Oy Vaginal delivery system
WO2009127825A1 (en) 2008-04-16 2009-10-22 Cipla Limited Topical combinations comprising an antimycotic agent and an antiviral agent
WO2009155118A1 (en) * 2008-05-30 2009-12-23 Reprotect, Inc. Compositions and methods for inactivation of pathogens at genital tract surfaces
EP2130531A1 (en) 2008-06-04 2009-12-09 Rolf Kullgren AB Vaginal suppository comprising lactic acid
EP2440560A1 (en) 2009-06-10 2012-04-18 Ultimorphix Technologies B.v. The succinate of tenofovir disoproxil
CA2839790A1 (en) * 2011-05-02 2012-11-08 Aptalis Pharmatech, Inc. Rapid dissolve tablet compositions for vaginal administration
CA2840571C (en) 2011-06-28 2020-03-24 Medicis Pharmaceutical Corporation High dosage mucoadhesive metronidazole aqueous-based gel formulations and their use to treat bacterial vaginosis
NZ703203A (en) * 2012-06-13 2016-07-29 Evofem Inc Compositions and methods for enhancing the efficacy of contraceptive microbicides
WO2015027071A1 (en) 2013-08-21 2015-02-26 Georgia Regents Research Institute, Inc. Gpr81 agonists and methods thereof for promoting production of secretory iga
CN114452298A (zh) 2013-12-19 2022-05-10 伊沃菲姆股份有限公司 使用基于藻酸的抗微生物化合物抑制炎症和疾病的组合物和方法
AU2015201042A1 (en) 2014-02-28 2015-09-17 Macfarlane Burnet Institute For Medical Research And Public Health Pty Ltd Therapeutic Method

Also Published As

Publication number Publication date
CN106029078A (zh) 2016-10-12
AU2014368971B2 (en) 2020-02-06
JP2020125298A (ja) 2020-08-20
US20160354394A1 (en) 2016-12-08
RU2691950C1 (ru) 2019-06-19
CN114452298A (zh) 2022-05-10
AU2014368971A1 (en) 2016-07-28
EP3082826A1 (en) 2016-10-26
KR102407408B1 (ko) 2022-06-10
EP3735966A1 (en) 2020-11-11
NZ722215A (en) 2019-02-22
KR20160103036A (ko) 2016-08-31
BR112016014506A2 (pt) 2017-10-31
IL246146A0 (en) 2016-07-31
US20220241301A1 (en) 2022-08-04
AU2020202835A1 (en) 2020-05-21
IL246146B2 (en) 2024-03-01
ZA201604862B (en) 2017-08-30
JP2017501227A (ja) 2017-01-12
ES2790703T3 (es) 2020-10-28
AU2020202835B2 (en) 2021-12-02
EP3082826B1 (en) 2020-03-11
DK3082826T3 (da) 2020-05-04
IL246146B1 (en) 2023-11-01
WO2015095793A1 (en) 2015-06-25
JP2022070924A (ja) 2022-05-13
BR112016014506B1 (pt) 2022-06-28
US20240299426A1 (en) 2024-09-12
US11337989B2 (en) 2022-05-24
RU2016129069A (ru) 2018-01-23
EP3082826A4 (en) 2017-08-23
MX2021001742A (es) 2021-04-19

Similar Documents

Publication Publication Date Title
MX2021001742A (es) Composiciones y metodos para inhibir la inflamacion y las enfermedades utilizando un compuesto antimicrobiano con base en acido alginico.
UA118256C2 (uk) Комбінований склад двох противірусних сполук
NZ716840A (en) Combination formulation of two antiviral compounds
PH12016500511A1 (en) Selective grp94 inhibitors and uses thereof
PH12015502161A1 (en) Therapeutic compounds and compositions
IN2015DN01197A (es)
IN2015DN01161A (es)
MX2016000927A (es) Sistemas para la supresion efectiva de una poblacion de moscas.
PL3082831T3 (pl) Kompozycje oparte na metylocyklodekstrynach do leczenia i/lub zapobiegania chorobom poprzez podwyższenie poziomu cholesterolu HDL
MX2015011193A (es) Compuestos antivirales.
NZ702087A (en) Pharmaceutical compositions and treatment of mastitis
CA2929436C (en) Compounds, pharmaceutical composition and methods for use in treating inflammatory diseases
IN2014CN00572A (es)
PH12016502130B1 (en) Novel pyrrolopyrimidine compound or salt thereof, pharmaceutical composition containing same, especially agent for prevention and/or treatment of tumors etc based on nae inhibitory effect
MX2018005004A (es) Compuestos de indazol substituidos como inhibidores de rorgammat y sus usos.
MX2015011198A (es) Compuestos antivirales.
WO2014182789A3 (en) Radiomitigating pharmaceutical formulations
EA201500736A1 (ru) Пиразолилкарбоксамиды i в качестве ингибиторов crac каналов
PH12015502115A1 (en) Compositions and methods for live, attenuated alphavirus formulations
EP3006434A4 (en) Novel compound derived from plant of genus quamoclit and composition containing same as active ingredient for preventing or treating diabetes
MX2015010790A (es) Derivados de anilina sustituidos con n-heteroarilo como antivirales de vhc.
EA201500737A1 (ru) Пиразолилкарбоксамиды ii в качестве ингибиторов crac каналов
GB2566235A (en) A novel formulation for rapid wound healing and control of infection
MX2015010892A (es) Compuestos antivirales.
MX2015011125A (es) Compuestos antivirales.